Klaria Pharma Holding Stock Total Debt
| KLAR Stock | SEK 0.60 0.10 20.00% |
Klaria Pharma Holding fundamentals help investors to digest information that contributes to Klaria Pharma's financial success or failures. It also enables traders to predict the movement of Klaria Stock. The fundamental analysis module provides a way to measure Klaria Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Klaria Pharma stock.
Klaria |
Klaria Pharma Holding Company Total Debt Analysis
Klaria Pharma's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Klaria Pharma Total Debt | 1.02 M |
Most of Klaria Pharma's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Klaria Pharma Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Klaria Pharma Holding has a Total Debt of 1.02 M. This is 99.96% lower than that of the Healthcare sector and 99.97% lower than that of the Drug Manufacturers - Specialty & Generic industry. The total debt for all Sweden stocks is 99.98% higher than that of the company.
Klaria Pharma Holding is considered the number one company in total debt category among its peers. Total debt of Drug Manufacturers - Specialty & Generic industry is now estimated at about 1.46 Million. Klaria Pharma totals roughly 1.02 Million in total debt claiming about 70% of equities under Drug Manufacturers - Specialty & Generic industry.Klaria Fundamentals
| Return On Equity | -0.88 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (9.48) % | |||
| Current Valuation | 88.14 M | |||
| Shares Outstanding | 63.1 M | |||
| Shares Owned By Insiders | 10.73 % | |||
| Shares Owned By Institutions | 9.75 % | |||
| Price To Earning | (18.43) X | |||
| Price To Book | 1.42 X | |||
| Price To Sales | 8.00 X | |||
| Gross Profit | 5.87 M | |||
| EBITDA | (39.41 M) | |||
| Net Income | (53.53 M) | |||
| Cash And Equivalents | 25.49 M | |||
| Cash Per Share | 0.47 X | |||
| Total Debt | 1.02 M | |||
| Current Ratio | 0.68 X | |||
| Book Value Per Share | 0.97 X | |||
| Cash Flow From Operations | (24.8 M) | |||
| Earnings Per Share | (1.72) X | |||
| Beta | 0.39 | |||
| Market Capitalization | 39.49 M | |||
| Total Asset | 118.31 M | |||
| Retained Earnings | (9 M) | |||
| Working Capital | 41 M | |||
| Current Asset | 44 M | |||
| Current Liabilities | 3 M | |||
| Z Score | 22.8 | |||
| Net Asset | 118.31 M |
About Klaria Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Klaria Pharma Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Klaria Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Klaria Pharma Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Klaria Stock Analysis
When running Klaria Pharma's price analysis, check to measure Klaria Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Klaria Pharma is operating at the current time. Most of Klaria Pharma's value examination focuses on studying past and present price action to predict the probability of Klaria Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Klaria Pharma's price. Additionally, you may evaluate how the addition of Klaria Pharma to your portfolios can decrease your overall portfolio volatility.